Zheng Quan Ri Bao Zhi Sheng·2025-11-03 12:07Core Points - On November 3, 2025, Laimei Pharmaceutical announced that its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (referred to as "Guangxi Investment Group"), signed an "Equity Increase Agreement" and "Share Transfer Agreement" with Guangxi Investment Group Financial Holding Co., Ltd. (referred to as "Guangxi Financial Holding") [1] - Guangxi Investment Group plans to increase capital by transferring 859,343,587 shares (26.89% of the total share capital) of its holding in the controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (referred to as "Zhongheng Group"), to Guangxi Financial Holding [1] - The transfer has been confirmed for compliance by the Shanghai Stock Exchange and received a "Securities Transfer Registration Confirmation" from China Securities Depository and Clearing Co., Ltd. on November 3, 2025, with the transfer date being October 31, 2025 [1] - After the completion of the share transfer registration, Guangxi Financial Holding will become the indirect controlling shareholder of the company, while Zhongheng Group remains the direct controlling shareholder, and the actual controller of the company is still the State-owned Assets Supervision and Administration Commission of the People's Government of Guangxi Zhuang Autonomous Region [1]